Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (291-300 of 404) with videos related to

Pageof 41
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2013
Recommendations for the management of hepatitis C virus infection among people who inject drugsGeert Robaeys, Jason Grebely, Stefan Mauss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL TrialsJason Grebely, Gregory J Dore, Stefan Zeuzem, et al.
Clinical Pharmacokinetics|August 30, 2022
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative ReviewMaría Patricia Hernández-Mitre, Steven Y C Tong, Justin T Denholm, et al.
Open Forum Infectious Diseases|November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical TrialsJason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trialStuart K Roberts, Martin D Weltman, Darrell H G Crawford, et al.
The Journal of Infectious Diseases|February 12, 2022
Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic ReviewBeth Catlett, Behzad Hajarizadeh, Evan Cunningham, et al.
The Lancet. HIV|June 6, 2022
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regressionSamira Hosseini-Hooshyar, Behzad Hajarizadeh, Sahar Bajis, et al.
The International Journal on Drug Policy|November 4, 2021
Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependenceMichael Farrell, Jeyran Shahbazi, Marianne Byrne, et al.
Drug and Alcohol Dependence|November 7, 2016
The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus malesJudith I Tsui, Ali Mirzazadeh, Judith A Hahn, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2025
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysisAdelina Artenie, Adam Trickey, Katharine J Looker, et al.
Pageof 41

Showing results (291-300 of 404) with videos related to

Sort By:
Pageof 41
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2013
Recommendations for the management of hepatitis C virus infection among people who inject drugsGeert Robaeys, Jason Grebely, Stefan Mauss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL TrialsJason Grebely, Gregory J Dore, Stefan Zeuzem, et al.
Clinical Pharmacokinetics|August 30, 2022
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative ReviewMaría Patricia Hernández-Mitre, Steven Y C Tong, Justin T Denholm, et al.
Open Forum Infectious Diseases|November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical TrialsJason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trialStuart K Roberts, Martin D Weltman, Darrell H G Crawford, et al.
The Journal of Infectious Diseases|February 12, 2022
Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic ReviewBeth Catlett, Behzad Hajarizadeh, Evan Cunningham, et al.
The Lancet. HIV|June 6, 2022
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regressionSamira Hosseini-Hooshyar, Behzad Hajarizadeh, Sahar Bajis, et al.
The International Journal on Drug Policy|November 4, 2021
Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependenceMichael Farrell, Jeyran Shahbazi, Marianne Byrne, et al.
Drug and Alcohol Dependence|November 7, 2016
The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus malesJudith I Tsui, Ali Mirzazadeh, Judith A Hahn, et al.
The Lancet. Gastroenterology & Hepatology|February 24, 2025
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysisAdelina Artenie, Adam Trickey, Katharine J Looker, et al.
Pageof 41